Recent Updates — PDSB
On October 20, 2026, PDS Biotechnology Corporation filed a Form 8-K to update its corporate presentation deck. The filing incorporates Exhibit 99.1, which details the company's oncology drug development programs, including clinical results for PDS0301 and PDS0101. The presentation notes that Dr. Patrick Soon-Shiong joined the Board of Directors following a September 2026 financing led by Nant Capital. It also outlines near-term catalysts with five data readouts anticipated between Q4 2026 and Q2 2028 across various indications including prostate cancer, colorectal cancer, and Kaposi sarcoma. PDS Biotechnology Corporation operates in the biotechnology industry, focusing on developing immunotherapies for solid tumors.
On October 18, 2026, Kamil Ali-Jackson, Stephen Glover, Gregory Freitag, and Otis Brawley resigned from the board of PDS Biotechnology Corporation. The company immediately appointed Deborah A. Ramsdell, John A. Dawson CBE, and Bruce Wendel as new directors to fill three vacancies, bringing total board members to seven. Each new director received a nonqualified stock option for 22,700 shares under the company's equity incentive plan. PDS Biotechnology is a late-stage immunotherapy company focused on developing cancer treatments.
PDS Biotechnology announced it will host a virtual key opinion leader event on October 15, 2026. The company plans to feature Jonathan M. Hernandez, M.D., an investigator with the Surgical Oncology Program at the National Cancer Institute’s Center for Cancer Research. Dr. Hernandez will join management to discuss clinical outcomes from the PDS0301 Phase 2 trials for advanced liver-associated cancers, specifically focusing on the metastatic colorectal cancer cohort. The event aims to provide an overview of trial results in patients with unresectable microsatellite stable or mismatch repair-proficient colorectal liver metastases. PDS Biotechnology is a clinical-stage biotechnology company focused on developing targeted immunotherapies for cancer.
PDS Biotechnology Corporation announced the publication of Phase 2 VERSATILE-002 trial results for its HPV16-targeted immunotherapy PDS0101 in combination with pembrolizumab in JAMA Oncology. The data showed a median overall survival of 39.3 months and an objective response rate of 36% in patients with CPS ≥ 1, outperforming standard-of-care benchmarks. Concurrently, the company reported the initial closing of up to $22.3 million in PIPE financing led by Nant Capital, alongside an exclusive negotiation agreement for PDS0101 licensing rights. PDS Biotechnology is a clinical-stage biotechnology company developing targeted immunotherapies and cancer vaccines.
PDS Biotechnology Corporation filed a Form 8-K to update its corporate presentation deck as of September 21, 2026. The filing highlights the company's strategic refocus on PDS0301 and notes that proceeds from a September 2026 financing led by Nant Capital enabled Dr. Patrick Soon-Shiong to join the Board of Directors. The presentation details clinical data for PDS0301 in metastatic colorectal cancer, including a 71.4% response rate at six months and approximately 80% 24-month survival. It also outlines ongoing trials for PDS0101 in HPV-positive head and neck cancer and mentions an additional financing tranche committed upon submission of a registrational Phase 3 protocol for PDS0301 to the FDA. PDS Biotechnology Corporation operates in the biotechnology industry, developing tumor-targeted immunotherapies for solid tumors.
PDS Biotechnology redeemed its Yorkville Promissory Note for approximately $4.6 million, terminating the debt instrument. Concurrently, the company closed a PIPE financing led by Nant Capital, raising gross proceeds of $11.3 million through the issuance of common stock and warrants at a unit price of $0.2825. As part of the transaction, Dr. Patrick Soon-Shiong and Mr. James Banaag were appointed to the Board of Directors, with Nant securing designation rights contingent on maintaining a 15% ownership stake. The company also granted NantWorks an exclusive option to negotiate a license for its PDS0101 compound. PDS Biotechnology is a clinical-stage biotechnology company focused on developing targeted immunotherapies and cancer vaccines.